Date: 2013-11-18
Type of information: Series B financing round
Company: Mission Therapeutics (UK)
Investors: Imperial Innovations (UK), Pfizer Venture Investments (USA), Sofinnova Partners (France), SR One (UK), Roche Venture Fund (Switzerland)
Amount: £ 20 million (€ 23.9 million)
Funding type: series B financing round
Planned used: The financing round will enable MISSION to advance its lead programmes for the treatment of various genetically defined cancers, through preclinical development and to exploit further the potential of its novel technology platform.
Others: * On November 18, 2013, Imperial Innovations Group plc has announced that it has increased its support for MISSION Therapeutics by committing £4.5m of a £20m funding round. Innovations had previously participated in a £6m round for MISSION in August 2011. Innovations is joined in the round by new investor Pfizer Venture Investments and other existing investors Sofinnova Partners, SR One and Roche Venture Fund.
MISSION was formed to exploit advances in the biology of the DNA damage response for the discovery of new classes of therapeutic agents with novel mechanisms of action. Utilising fundamental research principally generated in the laboratory of Professor Stephen Jackson, MISSION has progressed several small molecule discovery programmes focused on key enzymes in the ubiquitin pathway to selectively target difficult-to-treat cancers.
Therapeutic area: Cancer - Oncology
